← All trials
NCT06847126
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 25, 2025
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2026
- First posted
- Feb 26, 2025
- Last posted
- Apr 13, 2025
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Postgraduate Institute of Medical Education and ResearchLead sponsor
- Postgraduate Institute of Medical Education and ResearchSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.